Biocept has reported that its cerebrospinal fluid assay, CNSide, could identify tumour cells, as well as actionable mutations, in non-small cell lung cancer (NSCLC) patients with leptomeningeal carcinomatosis (LMC).

The latest data from a study permits the use of the test for targeted therapy decisions that could enhance outcomes and boost life expectancy, the company noted.

Carried out at the University of Utah Huntsman Cancer Institute, US, the study assessed the ability of the CNSide assay to identify and evaluate tumour cells in the cerebrospinal fluid of 15 patients.

Findings showed that CNSide identified tumour cells in all the analysed samples with LMC, while cytology identified tumour cells in only 40% of the samples.

Furthermore, the assay also detected actionable biomarkers in tumour cells, which aided oncologists to make targeted therapy decisions that reduced debilitating symptoms and improved patient survival by more than three years in certain cases.

The study data indicated that CNSide is highly sensitive compared to cytology, Biocept noted, adding that LMC patient survival can be extended by detecting and treating an actionable target.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biocept chief medical officer and medical director Michael Dugan said: “CNSide has demonstrated the ability to reliably detect and analyse tumour cells in the cerebrospinal fluid that may not be found in blood or tissue samples.

“The specific molecular targets identified in these tumour cells can help guide a physician’s choice of newer, more effective therapies and inform the response to therapy in a way that can really help these patients see an improvement of symptoms and live significantly longer lives.”

Between 3% and 9% of NSCLC patients develop LMC, a complication characterised by the spread of cancer to the membranes around the brain and spinal cord.

Usually, LMC is diagnosed through clinical analysis, imaging and cytology, all of which have reduced sensitivity, the company said.

If the condition is not treated, patients have an average life expectancy of just four to six weeks.

In April, Biocept initiated the full commercial launch of its CNSide assay, which helps identify and manage the treatment of metastatic cancers involving the central nervous system.